野生型胃肠间质瘤分子机制研究进展

Progress in understanding of molecular mechanisms of wild-type gastrointestinal stromal tumors

胃肠道间质瘤(gastrointestinal stromal tumor,GIST)是消化系最常见的间叶源性肿瘤,80%-95%GIST存在KIT或PDGFRA基因突变,未突变者称为野生型GIST(WT-GIST).目前证实,突变型GIST对酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)分子靶向治疗有效.但WT-GIST通常对TKI类药物不敏感,其分子理论基础、发生机制需明确阐述.

Gastrointestinal stromal tumors （GIST） are the most frequent mesenchymal tumors of the gastrointestinal tract, 80%-95% of which have KIT and PDGFRA gene mutations. GISTs without gene mutations, including KIT and PDGFRA gene mutations, are called wild- type GISTs （WT-GISTs）. The development of a molecular drug targeting tyrosine kinase inhibitor （TKI） has changed the therapeutic of GISTs with gene mutations; however, WT- GISTs are not sensitive to TKI. The molecular basis and mechanism of these characteristics should be elucidated.